Galatea Bio and Fabric Genomics, a GeneDx (WGS) company, announced a strategic collaboration to enhance genetic testing by incorporating rare pathogenic variant analysis and polygenic risk scoring to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel with PRS for cardiovascular traits, followed by hereditary cancer panels with PRS. The collaboration integrates Fabric Genomics’ platform with Galatea Bio’s StrataRisk PRS algorithms, utilizing Broad Clinical Lab’s Blended Genome – Exome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks